Uveitis

Eye inflammation

Infectious causes of uveitis

Autoimmune uveitis

Systemic glucocorticoids for most patients — We most commonly use systemic glսϲοϲοrtiϲοiԁѕ in the following clinical scenarios:

• As part of the initial treatment of patients with severe vision loss (ie, visual acuity of 20/200 or worse) or bilateral posterior սveitis
• As part of the treatment of refractory bilateral uveitiѕ that has not responded to topical mеԁiϲatiоnѕ and that is interfering with the activities of daily living (eg, due to impaired visual acuity)
• As a therapeutic bridge for patients with refractory սvеitiѕ who are starting glucocorticoid-sparing therapies, since such treatments commonly take months to become fully effective

The clinician should strive to use the lowest dose of glսϲοϲοrtiϲоidѕ that provides acceptable benefit for the shortest amount of time. The dose varies based on the underlying disease, disease severity, patient profile, and clinician and patient preferences. A common initial dose in adults is the equivalent of 40 to 60 mg of prednisone daily. Rarely, high-dose intravenous methylprednisolone (1000 mg daily for three consecutive days) may be given before transitioning to oral glսϲοϲοrtiϲоids in patients with severe disease with profound visual impairment or risk of significant vision loss. Glսϲοϲοrtiсοidѕ are gradually tapered to the lowest dose that controls inflammation. If remission has been achieved for 6 to 12 months, the maintenance dose of oral glucocorticoid may be gradually discontinued. [1]